What is the clinical evidence from this study?

Study design: Review. Population: Mitral regurgitation (MR). Intervention: Mitral valve transcatheter edge-to-edge repair (M-TEER).

What question did this study set out to answer?

This research aims to evaluate M-TEER as a treatment option for patients with mitral regurgitation, especially those at high surgical risk.

February 28, 2026

M-TEER—interventional repair of mitral valve regurgitation

Resultado clave

Mitral valve transcatheter edge-to-edge repair (M-TEER) is an established, safe, and effective alternative therapy for both primary and secondary mitral regurgitation in high-surgical-risk patients.

Puntos clave

This research aims to evaluate M-TEER as a treatment option for patients with mitral regurgitation, especially those at high surgical risk.
Review of key evidence from pivotal randomized controlled trials such as EVEREST II, COAPT, MITRA-FR, RESHAPE-HF2, and MATTERHORN.
Discussion on patient selection criteria for M-TEER.
Overview of ongoing studies in the field of M-TEER.
The safety and efficacy of M-TEER have been established in both primary MR and secondary MR groups through previous trials.
Recent updates in European guidelines expand M-TEER recommendations, particularly for secondary MR treatments.
New insights from current RCTs are paving the way for improved patient outcomes in high-risk categories.

PICO estructurado

Does M-TEER improve outcomes in patients with primary and secondary mitral regurgitation at high surgical risk?

Población

Patients with primary (PMR) and secondary mitral regurgitation (SMR) with high surgical risk

Intervención

Mitral valve transcatheter edge-to-edge repair (M-TEER)

M-TEER is a safe and effective treatment for high-surgical-risk patients with primary or secondary mitral regurgitation, supported by recent pivotal trials that have expanded European guideline recommendations.

Resumen

Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as an alternative therapy for mitral regurgitation (MR), addressing the unmet clinical need for patients with high surgical risk. Previous large randomized controlled trials (RCTs), including EVEREST II, COAPT, and MITRA-FR, have established the safety and efficacy of M‑TEER for both etiologies of MR: primary (PMR) and secondary MR (SMR). The field of SMR treatment has been updated by the recent RCTs RESHAPE-HF2 and MATTERHORN, which have expanded the recommendations of M‑TEER in the current European guidelines. This article summarizes key evidence from pivotal trials, discusses patient selection, and presents ongoing studies in the field of M‑TEER. Die kathetergestützte segelbasierte „Edge-to-Edge-Therapie“ der Mitralklappe (M-TEER) hat sich als eine alternative Therapie zur Behandlung der Mitralklappeninsuffizienz (MR) etabliert, um Patienten mit MR und hohem operativem Risiko zu behandeln. In den früheren großen randomisierten Studien EVEREST II, COAPT und MITRA-FR wurde die Sicherheit und Effizienz der M‑TEER in beiden Gruppen der MR nachgewiesen, nämlich der primären (PMR) und der sekundären MR (SMR). Insbesondere im Feld der SMR gab es Aktualisierungen durch die zuletzt veröffentlichten randomisierten Studien RESHAPE-HF2 und MATTERHORN, durch welche die Empfehlungen der aktuellen europäischen Leitlinien für M‑TEER erweitert wurden. Im vorliegenden Artikel werden die wichtigsten Erkenntnisse der entscheidenden Studien zusammengefasst, die Patientenselektion erörtert und laufende Studien zu M‑TEER vorgestellt.

Me gusta

Guardar